Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 9:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,847 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Degenerative Disease Clear all
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease

NCT02880956
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ABBV-8E12, placebo for ABBV-8E12
Drug
Lead sponsor
AbbVie
Industry
Eligibility
55 Years to 85 Years
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
38
States / cities
Phoenix, Arizona • Sun City, Arizona • Irvine, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2022 · Synced Sep 30, 2026, 9:16 PM EDT
Completed Phase 1 Interventional

Treatment -Resistant Neovascular Age-Related Macular Degeneration

NCT02332941
View directory record Official record
Conditions
Macular Degeneration
Interventions
Rituximab
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
41 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Sep 30, 2026, 9:16 PM EDT
Enrolling by invitation Phase 4 Interventional Accepts healthy volunteers

Imaging of Brain Amyloid Plaques in the Aging Population

NCT00950430
View directory record Official record
Conditions
Alzheimer's Disease, Dementia With Lewy Bodies, Frontotemporal Dementia, Vascular Dementia
Interventions
Pittsburgh Compound B (C-11 PiB), F-18 FDG, Tau (18-F-AV-1451)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 100 Years
Enrollment
8,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 30, 2026, 9:16 PM EDT
Completed Phase 2 Interventional

Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis

NCT00615693
View directory record Official record
Conditions
Uveitis, Posterior Uveitis, Panuveitis
Interventions
AEB071
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Sep 30, 2026, 9:16 PM EDT
Completed Not applicable Interventional

A Pilot Study to Evaluate an Osteogenic Protein 1 (OP-1) Putty Spinal System and an Autograft Spinal System

NCT00678171
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
TLIF with a PEEK Spacer System and XIA Spinal System
Device
Lead sponsor
Olympus Biotech Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
10
States / cities
Los Angeles, California • San Diego, California • Durango, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2014 · Synced Sep 30, 2026, 9:16 PM EDT
Terminated No phase listed Observational

MDR - Longevity IT Oblique and Offset Liners

NCT05980234
View directory record Official record
Conditions
Non-inflammatory Degenerative Joint Disease (NIDJD), Avascular Necrosis, Protrusio Acetabuli, Traumatic Arthritis, Slipped Capital Femoral Epiphyses, Fracture of the Pelvis, Diastrophic Variant, Osteoarthritis, Fused Hip
Interventions
Total Hip Arthroplasty with Longevity IT Oblique Liners, Total Hip Arthroplasty with Longevity IT Offset Liners
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Sep 30, 2026, 9:16 PM EDT
Active, not recruiting Not applicable Interventional

Adaptix RCT Evaluating Adaptix™ Versus PEEK Cages

NCT05182489
View directory record Official record
Conditions
Spinal Canal Stenosis, Spondylolisthesis, Osteophyte, Bony Growth Formation, Degenerative Disc Disease
Interventions
Medtronic Adaptix™ titanium implants, Medtronic CAPSTONE® PEEK cage
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Sep 30, 2026, 9:16 PM EDT
Completed Not applicable Interventional Results available

Pivotal Study of a Percutaneous Mitral Valve Repair System

NCT00209274
View directory record Official record
Conditions
Mitral Valve Insufficiency, Mitral Valve Regurgitation, Mitral Valve Incompetence, Mitral Regurgitation, Mitral Insufficiency
Interventions
Percutaneous mitral valve repair using MitraClip implant, Mitral valve repair or replacement surgery
Device · Procedure
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Sep 30, 2026, 9:16 PM EDT
Completed Phase 3 Interventional

A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration

NCT00061594
View directory record Official record
Conditions
Macular Degeneration
Interventions
rhuFab V2 (ranibizumab)
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
70
States / cities
Tucson, Arizona • Beverly Hills, California • Irvine, California + 60 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2014 · Synced Sep 30, 2026, 9:16 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results

NCT01657669
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
Intravitreal Aflibercept injection
Drug
Lead sponsor
Retina Research Institute, LLC
Other
Eligibility
50 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
3
States / cities
St Louis, Missouri • McAllen, Texas
Source: ClinicalTrials.gov public record
Updated Oct 27, 2017 · Synced Sep 30, 2026, 9:16 PM EDT
Completed No phase listed Observational

Osteocel® Plus in Transforaminal Lumbar Interbody Fusion (TLIF)

NCT00947583
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
Osteocel Plus
Biological
Lead sponsor
NuVasive
Industry
Eligibility
18 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Sep 30, 2026, 9:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects

NCT02103894
View directory record Official record
Conditions
Alzheimer's Disease (AD), Parkinson's Disease (PD), Chronic Traumatic Encephalopathy (CTE), Progressive Supranuclear Palsy (PSP), Frontal Temporal Dementia (FTD), Pick's Disease, Tauopathies
Interventions
[18F]T807 ([18F]MNI-777)
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Sep 30, 2026, 9:16 PM EDT
Completed Phase 2 Interventional Results available

A Study of an Encapsulated Cell Technology (ECT) Implant for Patients With Atrophic Macular Degeneration

NCT00447954
View directory record Official record
Conditions
Nonexudative Age-Related Macular Degeneration, Unspecified Eye, Intermediate Dry Stage
Interventions
High Dose NT-501 implant, Low Dose NT-501 implant, Sham
Combination Product · Other
Lead sponsor
Neurotech Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Beverly Hills, California • Hollywood, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Sep 30, 2026, 9:16 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Study of Social Behavior and Emotion in Frontotemporal Dementia, Alzheimer's Disease and Controls

NCT01147679
View directory record Official record
Conditions
Frontotemporal Dementia, Frontotemporal Degeneration, Alzheimer's Disease, Social Behavior
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
40 Years to 75 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2011 · Synced Sep 30, 2026, 9:16 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion

NCT00168324
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
700 µg Dexamethasone, 350 µg Dexamethasone, Sham Injection
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Sep 30, 2026, 9:16 PM EDT
Recruiting Not applicable Interventional

Intervention for Communication Quality of Life in Primary Progressive Aphasia

NCT07219680
View directory record Official record
Conditions
Primary Progressive Aphasia(PPA), Semantic Dementia, Logopenic Progressive Aphasia (LPA), Nonfluent Aphasia, Progressive, Progressive Aphasia, Semantic Variant Primary Progressive Aphasia (svPPA), Semantic Aphasia, Logopenic Variant Primary Progressive Aphasia, Logopenic Variant of Primary Progressive Aphasia (LPA), Logopenic Progressive Aphasia, Nonfluent Variant Primary Progressive Aphasia (nfvPPA), Nonfluent Progressive Aphasia
Interventions
Multicomponent Lexical Retrieval Cascade Training, Multicomponent Video Implemented Script Training in Aphasia
Behavioral
Lead sponsor
Maya Henry
Other
Eligibility
40 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 30, 2026, 9:16 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD

NCT00403442
View directory record Official record
Conditions
Macular Degeneration
Interventions
Verteporfin Therapy/ Drug: Bevacizumab
Device
Lead sponsor
Vitreous -Retina- Macula Consultants of New York
Other
Eligibility
50 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2008 · Synced Sep 30, 2026, 9:16 PM EDT
Completed No phase listed Observational

Natural History Study of CEP290-Related Retinal Degeneration

NCT03396042
View directory record Official record
Conditions
Blindness, Leber Congenital Amaurosis 10, Vision Disorders, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Retinal Disease, Retinal Degeneration
Interventions
Not listed
Lead sponsor
Editas Medicine, Inc.
Industry
Eligibility
3 Years to 99 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
4
States / cities
Miami, Florida • Boston, Massachusetts • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated May 19, 2022 · Synced Sep 30, 2026, 9:16 PM EDT
Recruiting Not applicable Interventional

A Phase I Feasibility Study of an Intracortical Visual Prosthesis (ICVP) for People With Blindness

NCT04634383
View directory record Official record
Conditions
Ocular Injury, Optic Nerve Diseases, Photoreceptor Degeneration, Blindness,Acquired
Interventions
WFMA - wireless floating microelectrode array
Device
Lead sponsor
Illinois Institute of Technology
Other
Eligibility
19 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 30, 2026, 9:16 PM EDT
Completed Not applicable Interventional

The Study of Physical Activity Rewards After Knee Surgery

NCT01970631
View directory record Official record
Conditions
Osteoarthritis, Degenerative Joint Disease
Interventions
Motivational Interviewing (MI), Financial Incentives
Behavioral · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Sep 30, 2026, 9:16 PM EDT
Recruiting Phase 2 Interventional

A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)

NCT06557460
View directory record Official record
Conditions
Dry Age-related Macular Degeneration, Geographic Atrophy
Interventions
Surgical implantation of the CPCB-RPE1 implant
Device
Lead sponsor
Regenerative Patch Technologies, LLC
Industry
Eligibility
55 Years to 90 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2040
U.S. locations
5
States / cities
Huntington Beach, California • Los Angeles, California • Lemont, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 30, 2026, 9:16 PM EDT
Completed Phase 3 Interventional

MAVERICK™ Total Disc Replacement- Pivotal Study

NCT00635843
View directory record Official record
Conditions
Spinal Diseases
Interventions
MAVERICK™ Disc, LT-CAGE® Lumbar Tapered Fusion Device and INFUSE® Bone Graft
Device
Lead sponsor
Medtronic Spinal and Biologics
Industry
Eligibility
18 Years to 70 Years
Enrollment
577 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
32
States / cities
Huntsville, Alabama • Daly City, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2013 · Synced Sep 30, 2026, 9:16 PM EDT
Completed Phase 3 Interventional Results available

A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

NCT03834753
View directory record Official record
Conditions
Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
Interventions
bevacizumab, ranibizumab
Biological
Lead sponsor
Outlook Therapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
50
States / cities
Tucson, Arizona • Arcadia, California • Beverly Hills, California + 46 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 30, 2026, 9:16 PM EDT
Terminated Phase 2 Interventional Results available

Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration

NCT02222207
View directory record Official record
Conditions
Macular Degeneration
Interventions
Regorafenib, ophthalmic oily suspension (BAY73-4506), Sham IVT, Ranibizumab, Placebo
Drug · Procedure
Lead sponsor
Bayer
Industry
Eligibility
50 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
37
States / cities
Tucson, Arizona • Arcadia, California • Beverly Hills, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2016 · Synced Sep 30, 2026, 9:16 PM EDT